Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC.
Tim F Greten, Lars A Ormandy, Annika Fikuart...
https://pubmed.ncbi.nlm.nih.gov/20139774/Actively Recruiting
Led by National Cancer Institute (NCI) · Updated on 2026-10-29
550
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are studying how the immune system responds to gastrointestinal cancers, which include cancers of the throat, stomach, gallbladder, liver, pancreas, and colon. The goal is to understand immune activity against these cancers by collecting and analyzing blood and tumor tissue samples from affected individuals. This observational study aims to support developing new treatments and diagnostic methods by investigating immune responses and the role of gut microbiota in cancer progression and therapy response. Participants will provide blood samples at several time points a baseline sample, additional samples at 2 and 4 months after baseline, and a final sample after completing their cancer treatment. Tumor tissue samples will be collected only if participants undergo surgery related to their cancer treatment. Stool samples may also be collected to study the intestinal microbiome. No treatment is administered as part of this study. Participants will attend between one and four visits for sample collection and evaluation, which include a physical examination and medical history review. Researchers will analyze samples using methods such as immune-monitoring and gene expression studies. The main outcome is the collection of samples over a 10-year period. This study involves no direct treatment but focuses on understanding cancer and immune interactions through ongoing sample collection and monitoring.
CONDITIONS
Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal Cancer
S
Stephanie N Hicks
T
Tim F Greten, M.D.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
National Cancer Institute (NCI)
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to several months depending on treatment schedule
Participants provide blood samples at baseline, 2 months, 4 months, and at treatment completion. Tumor tissue samples are collected if surgery is performed. Stool samples may also be collected to study the gut microbiome.
1 to 4 visits
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Tim F Greten, Lars A Ormandy, Annika Fikuart...
https://pubmed.ncbi.nlm.nih.gov/20139774/Noriho Iida, Amiran Dzutsev, C Andrew Stewart...
https://pubmed.ncbi.nlm.nih.gov/24264989/Romina S Goldszmid, Giorgio Trinchieri
https://pubmed.ncbi.nlm.nih.gov/22990891/National Cancer Institute (NCI)
Lead Sponsor